title: Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial.
abstract: BACKGROUND
  Administration of L-carnitine in patients with anterior acute myocardial infarction (AMI) prevents left ventricular remodeling. Current study was aimed to assess the effect of L-carnitine administration on mortality and heart failure in patients with anterior AMI.
  
  
  METHODS
  CEDIM 2 trial was a randomized, double-blind, multicenter, placebo-controlled trial planned to enroll 4,000 patients with acute anterior AMI. The trial was interrupted after the enrolment of 2,330 patients because of the lower than expected enrolment rate. The primary end point was a composite of death and heart failure at 6 months; 5-day mortality was the secondary end point.
  
  
  RESULTS
  During the 6-month follow-up, the primary end-point was not significantly different between the L-carnitine and placebo group (9.2 vs. 10.5%, p = 0.27). A reduction in mortality was seen in the L-carnitine arm on day 5 (secondary end-point) from randomization (HR = 0.61, 95% CI 0.37-0.98, p = 0.041).
  
  
  CONCLUSIONS
  In CEDIM 2 trial L-carnitine therapy led to a reduction in early mortality (secondary end-point) without affecting the risk of death and heart failure at 6 months in patients with anterior AMI, leading to a non-significant finding with respect to the primary end-point.
authors: Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy. giuseppe.tarantini.1@unipd.it
authors: Giuseppe
authors: G
authors: Tarantini
authors: Domenico
authors: D
authors: Scrutinio
authors: Paolo
authors: P
authors: Bruzzi
authors: Luca
authors: L
authors: Boni
authors: Paolo
authors: P
authors: Rizzon
authors: Sabino
authors: S
authors: Iliceto